Niraparib (hydrochloride)
Niraparib hydrochloride (MK-4827 hydrochloride) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib hydrochloride leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity[1][2][3].
Product Specifications
CAS Number
[1038915-64-8]
Product Name Alternative
MK-4827 (hydrochloride)
UNSPSC
12352005
Target
Apoptosis; PARP
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mk-4827-hydrochloride.html
Concentration
10mM
Purity
99.41
Solubility
DMSO : 250 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)
Smiles
NC(C1=CC=CC2=CN(C3=CC=C([C@H]4CNCCC4)C=C3)N=C21)=O.Cl
Molecular Formula
C19H21ClN4O
Molecular Weight
356.85
References & Citations
[1]Jones P, et al. Discovery of 2-{4-[ (3S) -piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827) : a novel oral poly (ADP-ribose) polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52 (22) :7170-85.|[2]Bridges KA, et al. Niraparib (MK-4827), a novel poly (ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget. 2014 Jul 15;5 (13) :5076-86.|[3]Wang L, et al. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. 2012 Dec;30 (6) :2113-20.|[4]Mirza MR, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec 1;375 (22) :2154-2164.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
PARP1; PARP2; PARP3; PARP4; TNKS1/PARP5A
Citation 01
Int J Biol Macromol. 2024 May 9:132275.|J Oncol. 2022 Apr 5;2022:2800488.|Acta Pharm Sin B. 2025 Oct 1.|Adv Sci (Weinh) . 2022 Oct;9 (30) :e2201210.|Adv Sci (Weinh) . 2025 Jul 16:e15585.|Am J Cancer Res. 2024 Jan 15;14 (1) :378-389.|Am J Pathol. 2024 Nov;194 (11) :2007-2022.|Appl Microbiol Biotechnol. 2019 Dec;103 (23-24) :9557-9568.|Biochem Pharmacol. 2025 May:235:116843.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biomed Pharmacother. 2025 Jun 16:189:118273.|bioRxiv. 2024 Jul 10:2024.07.09.602803.|bioRxiv. 2025 April 26.|bioRxiv. 2025 January 14.|bioRxiv. 2025 July 08.|BMC Cancer. 2022 Mar 23;22 (1) :312.|BMC Cancer. 2024 Dec 20;24 (1) :1562.|Cancer Cell. 2020 Dec 14;38 (6) :844-856.e7.|Cancer Chemother Pharmacol. 2017 Oct;80 (4) :861-867.|Cancer Discov. 2017 Sep;7 (9) :984-998.|Cancer Lett. 2022 Feb 1:526:180-192.|Cancer Res Commun. 2024 May 20.|Cancer Res. 2022 Jul 5;82 (13) :2361-2377.|Cancers (Basel) . 2023 May 11;15 (10) :2708.|Cancers (Basel) . 2024 Nov 5;16 (22) :3728.|Carcinogenesis. 2020 May 14;41 (3) :345-357.|Cell Death Dis. 2020 Apr 6;11 (4) :219.|Clin Cancer Res. 2017 Feb 15;23 (4) :1001-1011. |DNA Repair. 2019 Jan:73:64-70.|Drug Resist Updat. 2026 Jan:84:101319.|EBioMedicine. 2020 Sep;59:102923.|Elife. 2021 Jun 23:10:e69454.|Elife. 2022 Apr 27;11:e72464.|Faculty of Biology, University of Belgrade. 2019 Aug.|Front Oncol. 2021 Jul 9:11:681441.|HAL. archives-ouvertes. 2020 Dec 4.|Int Immunopharmacol. 2025 Sep 23:162:115158.|Int J Biol Sci. 2020 Feb 21;16 (8) :1363-1375.|Int J Cancer. 2025 Jan 15;156 (2) :389-402.|Int J Mol Sci. 2025 Mar 24;26 (7) :2921.|J Clin Invest. 2019 Mar 1;129 (3) :1211-1228.|J Exp Clin Cancer Res. 2025 Jun 16;44 (1) :175.|J Med Chem. 2024 Feb 22;67 (4) :2349-2368.|J Oncol. 2022 Apr 5;2022:2800488.|J Transl Med. 2025 Aug 5;23 (1) :860.|JCI Insight. 2023 Nov 8;8 (21) :e165268.|Life Sci Alliance. 2021 Oct 5;4 (12) :e202101144.|Mater Today Bio. 2020 Oct 22;8:100082.|medRxiv. 2020 Jan.|Mol Cancer Ther. 2023 Apr 3;22 (4) :447-458.|Mol Pharm. 2021 Dec 6;18 (12) :4371-4384.|Nat Biomed Eng. 2024 Feb;8 (2) :165-176.|Nat Commun. 2022 Nov 19;13 (1) :7107.|Neurooncol Adv. 2024 Nov 19;6 (1) :vdae187.|NPJ Precis Oncol. 2021 Jun 9;5 (1) :49.|NPJ Precis Oncol. 2025 Aug 30;9 (1) :306.|Nucl Med Biol. 2016 Dec;43 (12) :752-758. |Oncogene. 2022 Sep;41 (37) :4271-4281.|Patent. US20170226063A1.|Patent. US20180134664A1.|Patent. US20180362972A1.|Patent. US20190092732A1.|Patent. US20200078369A1|Patent. US20200129476A1|Patent. US20200148645A1|Patent. US20220048863A1.|Patent. US9932310B2.|PeerJ. 2023 Nov 29:11:e16314.|Research Square Preprint. 2022 Feb.|Research Square Preprint. 2024 Nov 06.|Sci Adv. Sci Adv. 2025 Apr 25;11 (17) :eadu0847.|Sci Rep. 2021 Sep 27;11 (1) :19138.|Theranostics. 2020 Jul 25;10 (21) :9477-9494. |Uppsala University. Department of Pharmaceutical Biosciences. 2022 Feb.|Urol Oncol. 2025 Sep 30:S1078-1439 (25) 00359-X.|J Med Chem. 2023 Mar 23;66 (6) :4106-4130.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Patent. US20210299137A1.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
125435-ML490 100 µL
CTDP1 (RNA Polymerase II Subunit A C-terminal Domain Phosphatase, TFIIF-associating CTD Phosphatase, FCP1) (MaxLight 490)
Ask
View Details 
MBS6197083-01 0.1 mL
PAK1 (p21 Protein (Cdc42/Rac)-Activated Kinase 1, MGC130000, MGC130001, PAKalpha) (MaxLight 405)
Ask
View Details MBS6197083-02 5x 0.1 mL
PAK1 (p21 Protein (Cdc42/Rac)-Activated Kinase 1, MGC130000, MGC130001, PAKalpha) (MaxLight 405)
Ask
View Details